• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Molecular overview of progressive familial intrahepatic cholestasis

    2021-01-15 08:59:52SriramAmirneniNilsHaepMohammadGadAlejandroSotoGutierrezJamesSquiresRodrigoFlorentino
    World Journal of Gastroenterology 2020年47期

    Sriram Amirneni, Nils Haep, Mohammad A Gad, Alejandro Soto-Gutierrez, James E Squires, Rodrigo M Florentino

    Abstract Cholestasis is a clinical condition resulting from the imapairment of bile flow. This condition could be caused by defects of the hepatocytes, which are responsible for the complex process of bile formation and secretion, and/or caused by defects in the secretory machinery of cholangiocytes. Several mutations and pathways that lead to cholestasis have been described. Progressive familial intrahepatic cholestasis (PFIC) is a group of rare diseases caused by autosomal recessive mutations in the genes that encode proteins expressed mainly in the apical membrane of the hepatocytes. PFIC 1, also known as Byler’s disease, is caused by mutations of the ATP8B1 gene, which encodes the familial intrahepatic cholestasis 1 protein. PFIC 2 is characterized by the downregulation or absence of functional bile salt export pump (BSEP) expression via variations in the ABCB11 gene. Mutations of the ABCB4 gene result in lower expression of the multidrug resistance class 3 glycoprotein, leading to the third type of PFIC. Newer variations of this disease have been described. Loss of function of the tight junction protein 2 protein results in PFIC 4, while mutations of the NR1H4 gene, which encodes farnesoid X receptor, an important transcription factor for bile formation, cause PFIC 5. A recently described type of PFIC is associated with a mutation in the MYO5B gene, important for the trafficking of BSEP and hepatocyte membrane polarization. In this review, we provide a brief overview of the molecular mechanisms and clinical features associated with each type of PFIC based on peer reviewed journals published between 1993 and 2020.

    Key Words: Progressive familial intrahepatic cholestasis; ATP8B1/familial intrahepatic cholestasis 1; ABCB11/bile salt export pump; ABCB4/multidrug resistance class 3; Intrahepatic cholestasis; Bile

    INTRODUCTION

    Among the liver functions, bile production is one of the most important. Hepatocytes and cholangiocytes work together in order to produce a mixture of organic and inorganic compounds that aid in the digestion process and excrete metabolites[1]. The formation of the final product, bile, is divided into two main processes: The formation and conjugation of the bile acids by the hepatocytes and the alkalization and dilution by the cholangiocytes. The bile can be stored in the gallbladder and secreted into the duodenum after a meal by a cholecystokinin stimulus. The detergent properties of bile give it the ability to break lipids into small particles, helping digestion[1].

    The impairment of bile flow is responsible for generating a clinical condition called cholestasis[2]. Alterations in the bile formation process, at the hepatocyte and/or cholangiocyte level, lead to some complications, potentially resulting in liver tumors or necessitating liver transplantation (LT)[2]. Several point mutations and pathways that contribute to this clinical condition have been elucidated. In hepatocytes, mutations and polymorphisms of the genes responsible for bile acid transporters, as well as farnesoid X receptor (FXR), an important transcription factor for the bile formation, were described[3,4]. In cholangiocytes, defects of the cystic fibrosis transmembrane conductance regulator (CFTR) and alterations in calcium (Ca2+) signaling contribute to cholestasis establishment and development[5,6].

    Nowadays, several cholestasis-related diseases have been described. At the biliary level, there are two such diseases: Primary sclerosing cholangitis and primary biliary cirrhosis. These diseases both result in nonfunctional cholangiocytes, leading to viscous bile[7-9]. Problems in the hepatocyte machinery are also related to cholestatic diseases. Through an unclear genetic, hormonal, and environmental mechanism, some women in late term pregnancy develop intrahepatic cholestasis due to the downregulation of some bile transporters of the hepatocyte membrane[10]. Some drugs, such as antimicrobials or acetaminophen, may also induce the impairment of bile flow through hepatocellular damage, resulting in cholestasis[11,12].

    Some autosomal recessive mutations of the bile acid membrane transporters that affect hepatocytes result in a group of diseases known as progressive familial intrahepatic cholestasis (PFIC). Historically, three types of PFIC were described: Type 1 due to mutations of the ATP8B1 gene, type 2 resulting from mutations of the ABCB11 gene, and type 3 caused by variations in the ABCB4 gene. Recently, new types of this disease have been reported. Here, we will discuss the recent molecular and clinical findings of not only PFIC 1, PFIC 2 and PFIC 3, but also of the new types that have recently been reported. This group of hereditary diseases causes severe cholestasis in infants and patients regularly have to undergo LT (Table 1).

    Table 1 Overview of progressive familial intrahepatic cholestasis subtypes

    BILE FORMATION

    Prior to describing the molecular and clinical features of PFIC, it is important to comprehend the bile formation process in order to understand how complex it is and how alterations could lead not only to hepatic disease, but also to dermatologic and neurologic symptoms.

    The main primary bile acids produced by the human liver are cholic acid (CA) and chenodeoxycholic acid (CDCA), generated by cholesterol metabolism[13]. In the hepatocytes, these compounds are conjugated with taurine and glycine in order to form bile salts, increasing their solubility. After the bile is secreted into the duodenum, the bile salts are reabsorbed by the brush border membrane of the terminal ileum. These reabsorbed bile salts return to the liver through portal blood circulation. A small amount of bile salts are lost in the feces but are replaced by de novo synthesis in the liver. Daily, the human liver produces around 200 to 600 mg of bile acids, replenishing the bile acid pool in the enterohepatic circulation[13].

    The hepatocellular part of bile formation can be divided into four stages. Stage 0 is characterized by the uptake of the compounds that will be processed to form the bile. This occurs at the basolateral hepatocyte membrane. Stage I is characterized by the activity of cytochrome P450 which turns the lipid compounds into soluble substrates for the next stages. Stage II is marked by the reactions that conjugate the bile acids. Finally, stage III is when the bile salts are secreted into the biliary canaliculus, the virtual space between two hepatocytes[1,13]. There are several different proteins and enzymes related to each stage, as shown in Figure 1.

    The two main pathways to produce bile acids involve 17 different enzymes located in the cytoplasm, endoplasmic reticulum, mitochondria, and peroxisomes[13]. In the classic pathway, also known as the neutral pathway, cholesterol is first metabolized by CYP7A1, generating CDCA. In the presence of CYP8B1, CDCA is converted into CA. The alternative pathway, known as the acid pathway, begins with cholesterol side chain metabolism by CYP27A1, which is expressed in the mitochondrial membrane[14]. The alternative pathway is important for bile acid production in neonates as well as in diseased livers.

    After bile acid synthesis and conjugation with the amino acids taurine and glycine, the bile salts are secreted into the canalicular region, a major step for bile flow. Most of the transporters belong to the ATP-binding cassette transporters (ABC transporters) superfamily[1]. As shown in Figure 1, there are several proteins involved in these steps and each one is responsible for transporting one compound in order to form the final product, the bile. Bile salt export pump (BSEP), multidrug resistance class 1 (MDR1), MDR3, MRP2, Breast Cancer Resistance Protein, sterolins 1 and 2, familial intrahepatic cholestasis 1 (FIC1) and others are examples of these transporters.

    After the bile salts are secreted into the canalicular space, the cholangiocytes are responsible for alkalinizing and diluting the bile by secreting bicarbonate (HCO3-) and water[1,15,16]. This process is initiated by the stimulation of secretin, a hormone produced in the S cells of the duodenum in response to the change in pH and presence of peptides after a meal. When this hormone binds to its receptor at the cholangiocyte basolateral membrane, it leads to a cytosolic increase in cAMP which activates CFTR, thereby releasing chloride (Cl-) into the bile duct lumen. This Cl-is exchanged with HCO3-, mediated by the chloride-bicarbonate exchanger which is expressed on the apical membrane of cholangiocytes[15]. The release of HCO3-is enhanced by local increases in Ca2+signaling that activate the M3 muscarinic receptor. When acetylcholine binds to the M3 muscarinic receptor, InsP3, a second intracellular messenger, is produced. This InsP3mediates the release of a Ca2+signal via the type 3 inositol 1,4,5-trisphosphate receptor. The Ca2+release near the apical membrane activates the Ca2+-dependent chloride channel, which releases more Cl-into the luminal space to be exchanged by the chloride-bicarbonate exchanger[6]. The activation of purinergic receptors also increases bicarbonate secretion, resulting in a pH increase. The presence of bicarbonate in the luminal space creates an osmotic gradient that is important for the flux of water from the cholangiocyte cytosol to the extracellular space. This transport is mediated by small integral membrane proteins known as aquaporins. The water makes the bile less viscous and leads the bile to the gallbladder, where it will be stored until a cholecystokinin stimulus occurs after a meal[1,15,16].

    Mutations in genes that encode proteins expressed in the hepatocyte canalicular membrane and involved in Phase III of bile formation are responsible for the development of a cholestatic disease known as PFIC. Now, we will provide a molecular and clinical overview of the three classic types of PFIC and discuss the newer types of this disease.

    Figure 1 Bile acid production. In phase 0, bile acids and other organic products are transported through the basolateral membrane of the hepatocyte. Phase I and II take place in the cytoplasm through activation and metabolization of differents CYPs. In phase III the bile acids are secreted into the biliary canalicus by the transmebrane transporters. NTCP: Na+-taurocholate cotransporting polypeptide; OATPs: Organic anion transporting polypeptides; OATs: Organic anion transporter; OCT1: Organic cation transporter 1; CYP7A1: Cytochrome P450 Family 7 Subfamily A Member 1; CYP8B1: Cytochrome P450 Family 8 Subfamily b Member 1; CYP27A1: Cytochrome P450 Family 27 Subfamily A Member 1; BSEP: Bile salt export pump; BRCP: Breast cancer resistance protein; ABCG5/8: ATP-binding cassette sub-family G member 5/8; MATE-1: Multidrug and toxin extrusion 1; MRP2: Multidrug resistance-associated protein 2; MDR1: Multidrug resistance class 1 glycoprotein; FIC1: Familial intrahepatic cholestasis 1; MDR3: Multidrug resistance class 3 glycoprotein; BC: Biliary canaliculus.

    PFIC 1

    PFIC type 1, also known as Byler’s disease, is caused by homozygous or compound heterozygous mutations of the ATP8B1 gene on chromosome 18 (18q21), which encodes the FIC1 protein[17]. FIC1 is part of the type 4 subfamily of P-type adenosine triphosphatases, which are involved in translocating phospholipids in membranes[18]. This protein, present at the apical membrane of hepatocytes, is thought to function as an aminophospholipid translocase, carrying phospholipids, specifically phosphatidylserine (PS) and phosphatidylethanolamine (PE), from the outside, ectoplasmic leaflet of the canalicular membrane, to the inside, cytoplasmic leaflet in hepatocytes[17-19]. When functioning normally, FIC1 protects the hepatocyte from high bile salt concentrations[17]. By maintaining the asymmetry of the plasma membrane, FIC1 guards the canalicular membrane from the detergent nature of hydrophobic bile salts present in the canalicular lumen[17,18].

    FIC1 was found to be successful at flopping phospholipids only when it was coexpressed with CDC50 proteins, specifically CDC50A[18]. This coexpression allows the FIC1-CDC50A heterodimer to leave the endoplasmic reticulum and localize to the apical membrane[18]. Mutations in CDC50A may also lead to the PFIC 1 phenotype if FIC1 fails to localize as a result[18]. In CDC50A-depleted intestinal cells, not only the apical membrane expression of FIC1 is reduced, but also the expression of the Solute Carrier Family 10 Member 2 (SLC10A2) also known as apical sodium-dependent bile acid transporter (ASBT)[20]. This transporter is responsible for the reuptake of bile acids in the intestines, so mutations in either the ATP8B1 gene or the CDC50A gene will impair localization of ASBT, reducing bile uptake[20]. This suggests that the FIC1-CDC50A heterodimer is involved in the localization of SLC10A2 to the apical membrane, resulting in bile salt malabsorption, which may be the cause of the diarrhea that PFIC 1 patients experience[20].

    There is also evidence that FIC1 is involved in the organization of the apical membrane of polarized cells[21]. In ATP8B1-deficient intestinal Caco-2 cells, the apical actin cytoskeleton was found to be disorganized, there was a loss of microvilli, and the translation of apical membrane protein mRNA was disrupted[21]. The reduced microvilli in the ATP8B1-deficient intestinal cells mirrors the loss of stereocilia on the apical membrane of inner hair cells in mice with an ATP8B1 mutation, which is linked to hearing loss, an event that is also observed in humans[21,22]. These examples support the case for the function of FIC1 in forming or stabilizing microvillar structures throughout the body[21].

    In the disease phenotype, the lipid flipping process does not occur, interfering with the secretion of bile salt from the hepatocytes[23]. Lower expression of FIC1 downregulates FXR expression, encoded by the NR1H4 gene[17]. The function of FXR is two-fold. In hepatocytes, elevated bile salts concentrations activate FXR, which induces the expression of the BSEP[17,19]. BSEP allows for the pumping of bile salts out of the hepatocyte into the canalicular lumen[17,19]. Additionally, when expressed in the intestines, FXR represses the expression of ASBT. By doing so, bile salt reabsorption is reduced in the intestines. The bile salt transport defect is secondary in the case of the ATP8B1 mutation. The accumulation of bile salts inside the hepatocytes, coupled with the absence of the protective lipid flipping by FIC1 has a cytotoxic effect, harming the cells and leading to the cholestatic phenotype[17,19].

    With the lack of lipid flipping, PS is freely present on the outer leaflet of the canalicular membrane[23]. This gives hydrophobic bile salts that exist in the canalicular space the opportunity to extract the PS from the membrane[23]. In normal hepatocytes, FIC1’s lipid flipping activity is necessary in maintaining the asymmetric and liquid ordered state of the outer leaflet of the canalicular membrane[23]. In diseased hepatocytes with an ATP8B1 mutation, the liquid ordered state becomes disordered because FIC1 is not able to flip the excess aminophospholipids from the outer to the inner leaflet[23]. This makes the membrane more susceptible to phospholipid, cholesterol, and ectoenzyme extraction[23]. Reduced cholesterol presence in the outer leaflet is vital in the functioning of certain integral membrane proteins such as BSEP (implicated in PFIC 2) and MRP1[23].

    Each specific mutation comes with its own presentation of cholestatic disease. The G308V mutation was first identified in the Amish population and in homozygotes with this mutation, the FIC1 protein is undetectable in the liver[24]. The D554N mutation was found in Greenland familial cholestasis and also resulted in reduced expression of FIC1[24]. The G1040R mutation, first found in two Saudi families, did not result in a significantly decreased FIC1 expression when compared to the wild-type[24]. As expected, the interaction between FIC1 and CDC50A was undetectable in both the G308V and D554N mutations[24]. It was, however, still present in the G1040R mutation, although at a much lower level than the wild-type[24]. This is likely the reason why these three FIC1 mutant proteins are not localized to the canalicular membrane in WIF-B9 cell models[24].

    Clinically, PFIC 1 presents with low gamma-glutamyl transferase (GGT) cholestasis[19]. Recurrent episodes of jaundice caused by hyperbilirubinemia, along with uncontrollable itching, or pruritus also occur[19]. Transaminases, as well as serum bile acids are elevated[19]. In infants with this disease, jaundice with pruritus, as well as hepatosplenomegaly develop early in life[19]. In severe cases, a progressive cholestasis presents along with portal hypertension[19]. Histologically, canalicular cholestasis, giant cell transformation, portal and lobular fibrosis, as well as lack of ductular proliferation are most common[17,19]. Because FIC1 is also expressed in cholangiocytes, enterocytes, and in the pancreas, there are extrahepatic manifestations of PFIC 1, setting it apart from the other types of intrahepatic cholestasis[17,19]. Some of these symptoms include diarrhea, stunted growth, exocrine pancreatic insufficiency, and progressive sensorineural hearing loss[17,19]. Nutritional deficiencies are also common, especially in fat-soluble vitamins A, D, E, and K[19].

    Children with PFIC 1 often require vitamin supplementation, as well as other dietary aids in order to manage malnutrition[19]. Ursodeoxycholic acid (UDCA) is the first-line of medication used to treat pruritus[19]. It is a hydrophilic bile acid that is hypothesized to induce the expression of BSEP and MDR3, improving cholestatic symptoms[19]. Rifampin and cholestyramine have also been used in order to reduce pruritus, but have not been as effective as UDCA[19]. In addition, CFTR folding correctors may be a promising future therapy to enhance the trafficking of FIC1 in the hepatocytes[19].

    In cases where medical management is inadequate, surgery is the next option. The purpose of these surgeries is to bypass the enterohepatic circulation, thereby lowering the amount of bile salts that are reabsorbed by the digestive system. Partial external biliary diversion (PEBD), partial internal biliary diversion (PIBD), and ileal exclusion (IE) have led to improvement in some cases[19]. PEBD has been shown to improve liver function, reduce serum bile acid levels, and slow progression of liver fibrosis in 80% of patients with either PFIC 1 or PFIC 2[25]. In this procedure, an external stomal conduit is created to divert bile flow outside of the body[19]. PIBD diverts bile flow from the gall bladder to the colon in order to bypass the terminal ileum, where bile salt reabsorption occurs[19]. This procedure has been shown to improve pruritus, as well as decrease bilirubin and plasma bile acid levels[19]. IE bypasses the distal 15% of the ileum to prevent bile acid reabsorption[19]. It provides relief from pruritus and may be used as a bridge to transplant[26]. Ileal adaptation may occur, reducing the effectiveness of this surgery[25].

    When no other treatment is successful, liver transplant is the final option. Lobular fibrosis may develop into cirrhosis and end stage liver disease[19]. There is no known association between FIC1 deficiency and tumorigenesis[19]. At this point, LT is indicated, which will improve cholestatic symptoms[19]. However, since FIC1 is expressed outside of the liver, extrahepatic symptoms may persist, or worsen[19]. Refractory diarrhea, coupled with the development of fatty liver changes in the allograft and fibrosis, may lead to re-transplant[27]. Ileal diversion during transplant may be used to potentially prevent these developments[19].

    PFIC 2

    Homozygous or compound heterozygous mutations in the ABCB11 gene (chromosome 2q31), which encodes the BSEP, results in PFIC 2[17]. BSEP is an adenosine triphosphate-binding cassette transporter involved in actively transporting bile salts out of hepatocytes into biliary canaliculi[17]. It is crucial in maintaining enterohepatic circulation of bile salts[17]. Mutations in BSEP interrupt the process of pumping bile out of hepatocytes, leading to increased intracellular bile salt concentrations which consequently damage the hepatocytes[17].

    FXR, activated in a heterodimer with retinoid X receptor α (RXRα), has been linked to upregulating enzymes and bile salt transporters when bound to bile salts in the cell[28]. BSEP is one of these bile salt transporters that FXR activates[28]. CDCA and the FXR/RXRα heterodimer collectively work together to transactivate the ABCB11 promoter[28]. The level of activation of the ABCB11 gene is dependent on the concentration of CDCA[28]. When more bile acids are present in the hepatocyte, more BSEP is made to maintain the equilibrium.

    There are over 200 mutations that have been linked with causing PFIC 2[19]. Some of these mutations cause splicing defects while most cause protein processing defects[29]. The majority of missense mutations resulted in a reduction of BSEP levels in vitro[29]. Some common mutations — G238V, D482G, G982R, R1153C, R1286Q, and ΔGly — cause the mutant protein to be retained in the endoplasmic reticulum[30]. Proteosomes are the main cellular component that breaks down these mutant proteins, but the D482G mutant protein can also be broken down by lysosomes[30]. The degradation occurs through Endoplasmic Reticulum Associated Degradation, part of the quality control system of the endoplasmic reticulum[30]. This process involves ubiquitination, retro-translocation out of the endoplasmic reticulum, and degradation by the proteasome[30].

    PFIC 2 presents with low GGT cholestasis as well as highly elevated transaminases, serum bilirubin, and alpha-fetoprotein (AFP) levels[17,19]. Jaundice, pruritus, scleral icterus, hepatomegaly, chronic skin picking, and reduced growth are also common[17,19]. Liver histology shows canalicular cholestasis, lobular and portal fibrosis, and hepatocellular necrosis[17]. Unlike PFIC 1, there is up to a 15% chance of cirrhosis developing into either hepatocellular carcinoma (HCC) or cholangiocarcinoma in patients with PFIC 2[19].

    Treatment of PFIC 2 is similar to PFIC 1. A promising therapy includes treatment with cell surface BSEP-enhancer molecules such as 4-phenylbutyrate (4PBA)[19]. 4PBA has been shown to improve liver function and pruritus in patients with certain mutations of BSEP[19]. Bile salt excretion was improved, although not completely[31]. 4PBA helps increase cell surface expression of the mutant BSEPs, likely altering a posttranscriptional mechanism[32]. This therapy works best when the mutation results in normal transport ability, but impaired membrane trafficking[32,33]. Biliary diversion procedures have a better response in cases where there is still some BSEP function than in cases where function is nonexistent[19].

    LT is the ultimate therapeutic option, but there is an additional risk in patients with PFIC 2. In severe cases, patients might develop allo-reactive antibodies specific to BSEP in the allograft, causing BSEP deficiency in the transplanted liver[19]. This happens in up to 8% of PFIC 2 patients who undergo LT[27]. Increased immunosuppression may prevent these antibodies from developing, but if the disease recurs, plasmapheresis to remove anti-BSEP antibodies, B-cell depleting antibody therapy, or allogeneic hematopoietic stem cell transplant may help[19,27]. If none of these therapies succeed, a second LT might be required[27].

    There have been many scientific advances offering hope for potential treatments for BSEP deficiency. One group led by Jillian Ellis developed a zebrafish model of BSEP deficiency[34]. Treating these zebrafish with rapamycin partially restored bile excretion as well as lengthened their lifespans[34]. The rapamycin likely localizes other transporters, such as MDR1, to the canaliculus in order to compensate for the lack of BSEP[34]. Rapamycin is an autophagy inducer, so the increased trafficking of MDR1 in rapamycin treated zebrafish might be the result of increased autophagy[34]. Another group led by Imagawa et al[33]generated a BSEP-deficient cellular model using patient cells[33]. They generated induced pluripotent stem cells (iPSCs) from peripheral blood mononuclear cells[33]. Then, they were able to differentiate these iPSCs into hepatocytelike cells that mimicked the BSEP deficiency of the patient from whom they were derived[33]. These cells had abnormal BSEP expression, as well as reduced biliary excretion[33]. When the cells were treated with 4PBA, there was an increase in membrane expression of BSEP[33]. In vitro models such as this one provide a practical way to test the effect of many different therapeutic agents on cells derived from individual patients themselves. Advances in stem cell research might make it possible to determine what drugs a patient will respond best to, based on their specific mutation, without having to test them all on the patient.

    PFIC 3

    Mutations in the ABCB4 gene, located on chromosome 7q21, which encodes the MDR3 glycoprotein, cause not only PFIC 3, but also other cholestasis related diseases such as gallbladder disease 1/low phospholipid-associated cholelithiasis (GBD1/LPAC), parenteral nutrition-associated liver disease, transient neonatal cholestasis and intrahepatic cholestasis of pregnancy[17]. This phosphatidylcholine (PC) flippase is localized only to the canalicular membrane of hepatocytes and consists of two cytoplasmic nucleotide binding domains and two transmembrane domains, each with six transmembrane segments. This structure facilitates the transport of PC out of the hepatocyte and into the biliary canaliculi. This process is supported by the overexpression of MDR3 in polarized cells, increasing the rate of transport of fluorescently labeled PC, but not other phospholipids. MDR2, the mouse homolog of human MDR3, has been used in knockout (KO) mice in order to model MDR3 deficiency[35]. The absence of the PC flippase leads to hepatocyte necrosis, dilated biliary canaliculus, periportal inflammation and bile duct proliferation[36]. These MDR2 KO animals develop HCC earlier, within 4-6 mo, due to an accumulation of carcinogenic factors[37-39]. The expression of human MDR3 in the MDR2 KO animals restores the function and histological features of the hepatocytes[38,40].

    Several variations in the ABCB4 gene have been described. Delaunay and colleagues used site-directed mutagenesis in a cell line model to show that the mutations I541F, L556R, and Q855L result in protein retention in the endoplasmic reticulum[41]. Another four mutations have no effect on MDR3 function: T424A and N510S had a normal pattern of canalicular expression with lower protein stability, while T175A and R652G had no detectable defect. Degiorgio et al[42]analyzed ABCB4 gene mutations in 68 PFIC 3 patients. The authors found 29 mutations in the coding region, including 23 missense, four nonsense, and two short insertion mutations in the gene. 10 of these mutations were present in the transmembrane domains (TM), specifically in TM7, involved in PC translocation[42]. Delaunay et al[41]devised a classification system for the various forms of these mutations[41]. Class I includes mutations that result in defective synthesis, class II covers variations that prevent protein maturation, class III mutants result in mature but defective proteins, class IV variations are unstable, and class V mutants have unknown pathogenicity[41]. These classifications are useful in determining potential therapies for patients, depending on their genotype.

    When MDR3 does not function properly, PC is absent from the biliary canaliculi. The free hydrophobic bile acids in this space will damage cholangiocytes, leading to cholestasis[19]. In addition, cholesterol is more likely to crystallize into stones, damaging liver structures by obstructing small bile ducts[25]. PFIC 3 often presents later on in life than both PFIC 1 and PFIC 2, as late as adulthood in some cases[19]. In early onset, pruritus, hepatosplenomegaly, variceal bleeding caused by portal hypertension, alcoholic stools, stunted growth, jaundice, reduced bone density, and learning disabilities have all been associated with MDR3 deficiency[17,19]. Adult onset can present anywhere from cholelithiasis to benign recurrent intrahepatic cholestasis (BRIC)[19]. Unlike PFIC 1 and 2, PFIC 3 presents with elevated GGT[19]. Transaminases, bilirubin, and alkaline phosphatase are elevated as well[17,19]. Although serum bile salt and cholesterol can be in the normal range, biliary phospholipids will be reduced[17]. Histological findings include nonspecific portal inflammation, portal fibrosis, cholestasis with bile duct proliferation, and slight giant cell hepatitis[17,19]. MDR3 expression upon staining will depend on the type of protein defect, with functional protein defects staining normally and truncated protein defects not staining[17,19]. Additionally, hepatocellular carcinoma and cholangiocarcinoma have been associated with PFIC 3[19].

    UDCA treatment has been effective in 70% of cases where the patient retains MDR3 expression and residual PC secretion[17]. Rifampin could also improve pruritus[19]. Chemical chaperones could improve MDR3 trafficking, depending on the specific mutation[43]. Biliary diversion procedures are not as successful with MDR3 deficiency because of the severity upon presentation[19]. LT is currently the only known curative treatment[19]. Gene therapy via adeno-associated virus has shown promise in restoring phospholipid excretion and preventing liver injury in murine models of PFIC 3[44]. This may be an alternative therapy for MRD3 deficiency in the near future.

    NEWER TYPES OF PFIC

    PFIC 4

    PFIC 4 is caused by a loss of function mutation in the tight junction protein 2 (TJP2), also called zona occludens 2, present on chromosome 9q21[17]. In the liver, this protein is involved in forming tight junctions by interacting with transmembrane tight junction proteins and the actin cytoskeleton[45]. Tight junctions are essential in the liver because they help prevent the leakage of biliary components into the liver parenchyma[46]. Claudin-1 (CLDN1) and claudin-2 (CLDN2) are two integral tight junction proteins that are expressed in the liver, aiding in the formation of tight junctions[45]. Normally, these two proteins are localized to the canalicular membrane, but in TJP2 mutation, CLDN1 fails to localize, especially in the parenchyma of the hepatic lobule[45,47]. These compromised tight junctions then allow cytotoxic bile salts to leak into the paracellular space, causing damage to the surrounding hepatocytes and cholangiocytes[19,45].

    This disease presents with severe cholestasis and low GGT levels[17]. Patients lack mutations in ATP8B1 and ABCB11 genes, excluding the diagnoses of PFIC 1 and PFIC 2. Extrahepatic symptoms have been reported in some patients, mainly in the neurological and respiratory systems[45]. This is likely related to the expression of TJP2 in every epithelial cell in the body[45]. The reason the liver is consistently affected by TJP2 deficiency is because of the particularly damaging nature of the bile acids present in the canaliculi[47]. Pathological findings include intracellular cholestasis, giant cell transformation, lack of TJP2 with staining, abnormal CLDN1 localization, and normal CLDN2 localization[19,47]. The lack of TJP2 could be tied to the nonsense mediated mRNA decay (NMD) process[45]. This process degrades mutant transcripts, such as TJP2 in the case of a mutation[45]. Even though the protein could have residual function, it is still degraded[45]. TJP2 was found to have low mRNA expression in PFIC 4 patients[45]. Western blotting revealed no TJP2 expression, indicating a possible link between the mutation in TJP2 and NMD[45].

    There have been several reports of HCC occurrence in patients suffering with TJP2 deficiency[48-50]. The exact mechanism of tumorigenesis has not yet been elucidated. In terms of treatment, there have been no reported cases of recurrence after LT[17].

    PFIC 5

    Loss of function mutations in the NR1H4 gene (chromosome 12q23), encoding FXR, result in PFIC 5[4,17]. FXR is a nuclear receptor activated by bile acids and directly involved in the expression of both BSEP and MDR3, proteins affected in PFIC 2 and PFIC 3 respectively[4]. This protein is activated by elevated bile acids levels in the ileum, inducing expression of fibroblast growth factor 19 (FGF19)[51]. In the liver, FGF19 binds to the fibroblast growth factor receptor 4/β-Klotho complex, which in turn represses cytochrome P450 7A1 (CYP7A1)[51]. Repression of this enzyme reduces de novo bile acid synthesis[51].

    Features of this disease include neonatal onset of normal GGT associated cholestasis, elevated serum bilirubin, elevated serum AFP levels, undetectable expression of BSEP in the bile canaliculi, and vitamin K independent coagulopathy[4]. This vitamin K independent coagulopathy is unique to PFIC 5 and has been shown to be a direct result of FXR mutation[4]. Three fibrinogen genes, as well as some coagulation factors have been linked with FXR-dependent induction, which does not occur in PFIC 5 patients[4]. Histological findings are intralobular cholestasis with ductular reaction, hepatocellular ballooning, fibrosis progressing into micronodular cirrhosis, and giant cell transformation[19]. NR1H4/FXR associated PFIC is very rare as only eight cases have been reported in the literature[4,52,53]. LT has been used, but steatosis in the transplanted liver has been reported in some of these cases[4,53]. UDCA and rifampicin may be used in order to improve pruritus, but ASBT inhibitors, as well as FXR agonists such as obeticholic acid, both show promise as future medical therapies[51,54].

    PFIC associated with MYO5B defects

    The MYO5B gene (chromosome 18q21.1) encodes an actin-associated molecular motor known as MYO5B[17]. The interaction between MYO5B and RAS-related GTP-binding protein 11A (RAB11A) is essential for the polarization of epithelial cells, as well as localizing BSEP to the canalicular membrane[55]. Diminished activity of the MYO5B/RAB11A recycling endosome pathway is related to disrupting the localization of BSEP[56]. Mutations of this gene are associated with microvillus inclusion disease (MVID) which affects the enterocytes and leads to diarrhea, as well as malabsorption[57]. Mislocalized apical brush border proteins, villus atrophy, and the presence of microvillus inclusion bodies are all associated with MVID[57-60]. Total parenteral nutrition (TPN) is required throughout life, but it has been associated with a high risk of sepsis and small bowel transplant[61].

    MVID has been associated with cholestatic liver disease, which possibly occurs as a result of TPN[57]. In fact, MYO5B gene mutations may account for 20% of the idiopathic low-GGT associated cholestasis in pediatric patients[60]. This cholestasis presents with low to normal GGT levels, jaundice, pruritus, mildly elevated Alanine transaminase and Aspartate transaminase, elevated serum BS levels, hepatomegaly, portal and lobular fibrosis, and giant cell transformation[17,19,60]. Staining of BSEP and MDR3 may show that they are present, but not localized to the canalicular membrane, although this may not occur in every patient[19,60].

    There is evidence for different phenotypes resulting from the type of MYO5B gene mutation[55,60]. Mutations with limited effects on MYO5B functionality are linked with canalicular transport defects in hepatocytes but are not known to have as significant of an effect on enterocytes[60]. In more damaging mutations, the hepatocyte defects may be greater, but there will also be enterocyte disruption[60]. Enterocytes will not uptake bile acids as efficiently, reducing the amount of bile product taken back to the liver via enterohepatic circulation, potentially alleviating or protecting against cholestatic symptoms[60]. There seems to be an inverse relationship between cholestasis and intestinal function. UDCA, rifampin, and cholestyramine have been used to treat pruritus in these patients[19]. If medical treatment is not sufficient, PEBD may be successful[19]. When symptoms necessitate transplant, combined bowel-liver transplant should be considered in order to avoid post-transplant onset of cholestasis[60].

    HOW TO STUDY PFIC?

    After the identification of mutations in patients, several models have been created to better understand not only the pathophysiology of PFIC, but also to investigate drugs and treatments. The first model is the use of a cell line with mutations in PFIC related genes to study the mechanisms of these variants on both the molecular and clinical level. van der Velden et al[62], using different cell lines, studied some FIC1 mutations[62]. Delaunay et al[41], studied MDR3 gene mutations using HepG2 as a model. A second option to study PFIC are knockout mice[63]. Some studies have reported the use of ABCB11-/-mice as a model for PFIC 2, however the clinical findings are less severe than those of humans[63]. MDR2 KO mice are used to model complications resulting from MDR3 deficiency in humans and are also used to study treatments for all MDR3-related diseases[35,40].

    In 2012, when Shinya Yamanaka and John B. Gurdon were awarded The Nobel Prize in Physiology or Medicine for their discovery in pluripotency, a new method to study PFIC became available. The possibility of transforming any somatic cell into an iPSCs was revolutionary. Okita and colleagues used plasmids to express c-Myc, SRYbox transcription factor 2 (Sox2), Kruppel-like factor 4, and octamer-binding transcription factor 4 (Oct4) in reprogrammed mature cells[64]. This last set of genes is known as Yamanaka’s Factors. However, there are many different protocols to generate iPSCs. Si-Tayeb et al[65]used the expression of Oct4, Sox2, Nanog, and Lin-28 homolog A in a lentivirus delivery system to generate iPS cells[65]. In this way, Imagawa et al[33]generated a BSEP-deficient cellular model using patient cells and tested the effects of 4PBA treatment on protein expression and localization[33]. With this system of reprogramming cells, and access to patient cells with different mutations, a new model became available to better understand the various types of PFIC. The possibility of differentiating these cells into liver cells, such as hepatocytes and cholangiocytes, gives researchers the opportunity to test potential treatments in vitro. This can be extremely useful since very few patients have these rare diseases and are available to enroll in clinical trials. Large scale drug trials may not be feasible.

    CONCLUSION

    PFIC is a rare disease that affects the bile secretion process of the hepatocytes due to alterations in the proteins involved, as shown in Figure 2. Better understanding of the molecular alterations in this context is necessary to elucidate new targets and pathways that could be the focus of new treatments in the future. With advances in inducing pluripotent cells, a new model that is more precise and closer to humans has become available. Also, the progress in gene editing will help in the development of new models and potentially be used as a treatment method in the future.

    Figure 2 The molecular mechanisms behind progressive familial intrahepatic cholestasis. A: The classic types of Progressive Familial Intrahepatic Cholestasis (PFIC). PFIC 1 is related to mutations in the genes that encode the flippase familial intrahepatic cholestasis 1, which flips phospholipids in the plasma membrane. Mutations in the bile salt export pump (BSEP) protein, a bile salt transporter, results in PFIC 2. The third type of PFIC is caused by mutations in the gene that encodes the Multidrug resistance class 3 glycoprotein (MDR3) protein, another lipid flippase; B: The newer types of PFIC. Mutations in the tight junction protein-2 protein, which prevents the mixing of blood and bile acids, are responsible for PFIC 4. PFIC 5 is a result of mutations in the farnesoid X receptor protein, a transcription factor important for BSEP and MDR3 ecpression. Mutations in Myosin VB result in a PFIC phenotype because the trafficking of the BSEP protein from the endoplasmic reticulum to the plasma membrane is disrupted. PFIC: Progressive Familial Intrahepatic Cholestasis; FIC1: Familial intrahepatic cholestasis 1; BSEP: Bile salt export pump; MDR3: Multidrug resistance class 3 glycoprotein; TJP2: Tight junction protein-2; FXR: Farnesoid X receptor.

    亚洲人成伊人成综合网2020| 深夜精品福利| 一区福利在线观看| 日韩欧美一区二区三区在线观看| 一区福利在线观看| 丰满的人妻完整版| 长腿黑丝高跟| 成在线人永久免费视频| 综合色av麻豆| 国产精品,欧美在线| 欧美午夜高清在线| 丰满人妻一区二区三区视频av | 欧美中文综合在线视频| 亚洲国产精品久久男人天堂| 国产精品 欧美亚洲| 亚洲欧洲精品一区二区精品久久久| 免费看日本二区| 99热这里只有精品一区 | 成年版毛片免费区| 黑人巨大精品欧美一区二区mp4| 亚洲人成网站在线播放欧美日韩| 不卡一级毛片| 日韩人妻高清精品专区| 亚洲av成人不卡在线观看播放网| 久久人人精品亚洲av| 一级a爱片免费观看的视频| 99久久精品热视频| 免费电影在线观看免费观看| www.999成人在线观看| 成人特级av手机在线观看| 国内毛片毛片毛片毛片毛片| 亚洲欧美一区二区三区黑人| 免费人成视频x8x8入口观看| 国产亚洲av嫩草精品影院| 在线观看免费午夜福利视频| 国产69精品久久久久777片 | 国产三级中文精品| 亚洲自偷自拍图片 自拍| 国产成人av激情在线播放| 久久久久国产一级毛片高清牌| 美女扒开内裤让男人捅视频| 国产aⅴ精品一区二区三区波| 久久午夜综合久久蜜桃| 久久久久精品国产欧美久久久| 91老司机精品| 小蜜桃在线观看免费完整版高清| 不卡av一区二区三区| 亚洲欧美精品综合一区二区三区| 夜夜看夜夜爽夜夜摸| 好男人电影高清在线观看| 美女午夜性视频免费| 亚洲激情在线av| 九色成人免费人妻av| 亚洲av第一区精品v没综合| 欧美成人一区二区免费高清观看 | 我的老师免费观看完整版| 亚洲国产精品sss在线观看| 久久99热这里只有精品18| 老汉色av国产亚洲站长工具| 亚洲国产欧美人成| 亚洲精品中文字幕一二三四区| 在线观看午夜福利视频| 真人一进一出gif抽搐免费| 亚洲成a人片在线一区二区| 法律面前人人平等表现在哪些方面| 免费观看精品视频网站| 国产成人精品久久二区二区免费| 国内精品一区二区在线观看| 国产精品久久久久久久电影 | 国产黄片美女视频| av在线蜜桃| 三级男女做爰猛烈吃奶摸视频| 99视频精品全部免费 在线 | 高清毛片免费观看视频网站| 真人一进一出gif抽搐免费| 久久久国产成人精品二区| 国产又黄又爽又无遮挡在线| 9191精品国产免费久久| 一个人看的www免费观看视频| 亚洲一区二区三区色噜噜| 精品久久久久久,| 欧美午夜高清在线| 日本免费a在线| 毛片女人毛片| 欧美一级毛片孕妇| 亚洲在线自拍视频| 成人国产综合亚洲| 亚洲专区中文字幕在线| 免费电影在线观看免费观看| 我要搜黄色片| av女优亚洲男人天堂 | 男女下面进入的视频免费午夜| 99在线人妻在线中文字幕| 午夜福利在线观看吧| 欧美3d第一页| 亚洲在线观看片| 免费看光身美女| 两个人的视频大全免费| avwww免费| 淫秽高清视频在线观看| 亚洲成av人片免费观看| 亚洲avbb在线观看| 99国产精品99久久久久| 日本黄色视频三级网站网址| 97碰自拍视频| 丰满的人妻完整版| 俄罗斯特黄特色一大片| 午夜福利在线观看吧| 久9热在线精品视频| 精品久久久久久成人av| 中文字幕久久专区| 国产免费男女视频| 麻豆久久精品国产亚洲av| 啦啦啦免费观看视频1| 亚洲国产欧洲综合997久久,| 性色av乱码一区二区三区2| 给我免费播放毛片高清在线观看| 最新在线观看一区二区三区| 亚洲欧美日韩高清在线视频| 变态另类成人亚洲欧美熟女| 嫩草影视91久久| 免费电影在线观看免费观看| 亚洲av电影在线进入| 国模一区二区三区四区视频 | 18禁观看日本| 久久婷婷人人爽人人干人人爱| 亚洲国产欧美人成| 嫩草影院入口| 最新在线观看一区二区三区| 国产欧美日韩精品一区二区| 黑人巨大精品欧美一区二区mp4| 国产男靠女视频免费网站| 宅男免费午夜| 亚洲七黄色美女视频| 亚洲成av人片免费观看| 成年免费大片在线观看| 淫妇啪啪啪对白视频| 免费av不卡在线播放| 神马国产精品三级电影在线观看| 精品国产三级普通话版| 亚洲无线在线观看| 国模一区二区三区四区视频 | 欧美一区二区精品小视频在线| 99久久精品热视频| a级毛片a级免费在线| 免费大片18禁| 午夜福利视频1000在线观看| 少妇的丰满在线观看| 淫妇啪啪啪对白视频| 老司机在亚洲福利影院| 男人舔奶头视频| 97超视频在线观看视频| 偷拍熟女少妇极品色| 午夜福利视频1000在线观看| 色综合欧美亚洲国产小说| 在线国产一区二区在线| 在线观看免费视频日本深夜| 亚洲成人中文字幕在线播放| 国产午夜精品久久久久久| 免费搜索国产男女视频| 美女高潮的动态| 啦啦啦韩国在线观看视频| 国产精品国产高清国产av| 亚洲av成人不卡在线观看播放网| 88av欧美| 久久久久九九精品影院| 国产 一区 欧美 日韩| 99视频精品全部免费 在线 | 亚洲专区字幕在线| av天堂在线播放| 国产精品亚洲一级av第二区| 黑人欧美特级aaaaaa片| 欧美日韩亚洲国产一区二区在线观看| 成年免费大片在线观看| 中文字幕精品亚洲无线码一区| 久久这里只有精品19| 特大巨黑吊av在线直播| 欧美3d第一页| 三级毛片av免费| 国产日本99.免费观看| 亚洲成a人片在线一区二区| 男人的好看免费观看在线视频| 欧美激情在线99| 啪啪无遮挡十八禁网站| 成人无遮挡网站| 中亚洲国语对白在线视频| 丝袜人妻中文字幕| 久久性视频一级片| 非洲黑人性xxxx精品又粗又长| 最新在线观看一区二区三区| 99久久成人亚洲精品观看| 精品久久久久久久久久免费视频| 国产亚洲精品综合一区在线观看| 日本熟妇午夜| 日韩欧美 国产精品| 99re在线观看精品视频| 久久久国产欧美日韩av| 亚洲专区中文字幕在线| 欧美日韩综合久久久久久 | 手机成人av网站| 欧美绝顶高潮抽搐喷水| 久久久久国产精品人妻aⅴ院| 动漫黄色视频在线观看| 天天躁狠狠躁夜夜躁狠狠躁| 1024香蕉在线观看| 性色av乱码一区二区三区2| 久久九九热精品免费| 精品日产1卡2卡| 99精品在免费线老司机午夜| 日本熟妇午夜| 精品国产乱子伦一区二区三区| 国产成+人综合+亚洲专区| 国产成人啪精品午夜网站| 国产精品永久免费网站| 精品国内亚洲2022精品成人| 免费在线观看日本一区| 国产1区2区3区精品| 国产亚洲精品一区二区www| 久久久久国产精品人妻aⅴ院| 国产亚洲av高清不卡| 一进一出抽搐gif免费好疼| 午夜影院日韩av| 国产午夜精品久久久久久| 午夜亚洲福利在线播放| 俺也久久电影网| 18禁黄网站禁片午夜丰满| 亚洲第一电影网av| 欧美乱码精品一区二区三区| 亚洲一区二区三区色噜噜| 久久精品夜夜夜夜夜久久蜜豆| 国产午夜精品久久久久久| 高清毛片免费观看视频网站| 国产单亲对白刺激| 成人鲁丝片一二三区免费| 国产又黄又爽又无遮挡在线| 免费在线观看视频国产中文字幕亚洲| 午夜福利高清视频| 国产精品,欧美在线| 国产精品香港三级国产av潘金莲| 琪琪午夜伦伦电影理论片6080| 亚洲五月天丁香| 女人被狂操c到高潮| 99热精品在线国产| 免费无遮挡裸体视频| 日韩欧美在线乱码| 免费在线观看影片大全网站| 久久精品aⅴ一区二区三区四区| 极品教师在线免费播放| 国产欧美日韩一区二区精品| 午夜激情欧美在线| 老司机午夜十八禁免费视频| tocl精华| 国产成人一区二区三区免费视频网站| 亚洲色图 男人天堂 中文字幕| 日韩高清综合在线| 久久这里只有精品19| 99精品在免费线老司机午夜| 国产亚洲av高清不卡| 国产精品香港三级国产av潘金莲| 亚洲av电影在线进入| 搡老妇女老女人老熟妇| 桃红色精品国产亚洲av| 精品无人区乱码1区二区| www国产在线视频色| 小蜜桃在线观看免费完整版高清| 麻豆成人av在线观看| 黄色 视频免费看| 少妇丰满av| 99国产综合亚洲精品| 欧美日韩福利视频一区二区| 中文字幕最新亚洲高清| 久久精品亚洲精品国产色婷小说| 我的老师免费观看完整版| 久久婷婷人人爽人人干人人爱| 亚洲欧美一区二区三区黑人| 久久这里只有精品19| 真人做人爱边吃奶动态| 国内少妇人妻偷人精品xxx网站 | 日韩欧美三级三区| 91久久精品国产一区二区成人 | 听说在线观看完整版免费高清| 99riav亚洲国产免费| 亚洲男人的天堂狠狠| 高清在线国产一区| 国产激情偷乱视频一区二区| 韩国av一区二区三区四区| 精品不卡国产一区二区三区| 三级男女做爰猛烈吃奶摸视频| 一进一出抽搐gif免费好疼| 国产高清视频在线观看网站| 高清毛片免费观看视频网站| 高清在线国产一区| 黄色成人免费大全| av欧美777| 91在线精品国自产拍蜜月 | 午夜福利视频1000在线观看| 久久这里只有精品19| 国产综合懂色| 曰老女人黄片| 国产午夜福利久久久久久| 国产精品久久久人人做人人爽| 男女之事视频高清在线观看| 好男人在线观看高清免费视频| 欧美极品一区二区三区四区| tocl精华| 久久精品国产99精品国产亚洲性色| 精品一区二区三区av网在线观看| 熟妇人妻久久中文字幕3abv| 麻豆久久精品国产亚洲av| 一a级毛片在线观看| 免费看美女性在线毛片视频| 成人av在线播放网站| 亚洲天堂国产精品一区在线| 免费av不卡在线播放| 天天躁狠狠躁夜夜躁狠狠躁| 性色av乱码一区二区三区2| 性欧美人与动物交配| 免费看光身美女| 在线视频色国产色| 国产成人精品久久二区二区91| 欧美日韩亚洲国产一区二区在线观看| 曰老女人黄片| 18禁观看日本| 久久精品影院6| 亚洲人与动物交配视频| 美女被艹到高潮喷水动态| 国产乱人视频| 午夜福利免费观看在线| 女警被强在线播放| 夜夜躁狠狠躁天天躁| 国产一区二区三区视频了| 99在线人妻在线中文字幕| 久9热在线精品视频| 日韩大尺度精品在线看网址| 黄色成人免费大全| 精华霜和精华液先用哪个| 亚洲精品中文字幕一二三四区| 成人三级做爰电影| 亚洲自偷自拍图片 自拍| 精华霜和精华液先用哪个| 精品久久久久久久毛片微露脸| 午夜免费激情av| 亚洲国产精品久久男人天堂| 久久精品国产综合久久久| 全区人妻精品视频| 美女大奶头视频| 国产一区二区在线av高清观看| 亚洲精品久久国产高清桃花| 亚洲天堂国产精品一区在线| 成年女人看的毛片在线观看| 深夜精品福利| 亚洲人与动物交配视频| 熟妇人妻久久中文字幕3abv| 国产精品av视频在线免费观看| 露出奶头的视频| 亚洲成av人片免费观看| 国产人伦9x9x在线观看| 成年版毛片免费区| 国产精品久久久av美女十八| 69av精品久久久久久| 日本三级黄在线观看| av福利片在线观看| 国产91精品成人一区二区三区| 最近最新中文字幕大全免费视频| 欧美色欧美亚洲另类二区| 国产午夜精品论理片| 婷婷精品国产亚洲av在线| 欧美激情在线99| 级片在线观看| 黄色 视频免费看| av在线天堂中文字幕| 国产单亲对白刺激| 老司机在亚洲福利影院| 宅男免费午夜| 欧美成狂野欧美在线观看| 美女被艹到高潮喷水动态| 久久人人精品亚洲av| 一个人免费在线观看电影 | 久久国产精品影院| 少妇人妻一区二区三区视频| 偷拍熟女少妇极品色| 一级作爱视频免费观看| 观看免费一级毛片| 亚洲成人免费电影在线观看| 啦啦啦免费观看视频1| 国产亚洲欧美在线一区二区| 别揉我奶头~嗯~啊~动态视频| 国内精品久久久久精免费| 婷婷精品国产亚洲av在线| 两个人视频免费观看高清| 又爽又黄无遮挡网站| 天天一区二区日本电影三级| 亚洲美女视频黄频| 亚洲色图 男人天堂 中文字幕| 中文字幕av在线有码专区| 午夜免费成人在线视频| 观看美女的网站| 欧美丝袜亚洲另类 | 制服人妻中文乱码| 每晚都被弄得嗷嗷叫到高潮| 午夜免费观看网址| 亚洲欧美日韩卡通动漫| 亚洲一区高清亚洲精品| 亚洲专区字幕在线| 午夜免费观看网址| 99在线视频只有这里精品首页| 国产精品 欧美亚洲| 国产三级中文精品| 国产一区二区在线av高清观看| 精品无人区乱码1区二区| 欧美乱色亚洲激情| 丁香欧美五月| a级毛片在线看网站| 亚洲在线观看片| 精品电影一区二区在线| 床上黄色一级片| 少妇的丰满在线观看| 国产亚洲精品av在线| 久久99热这里只有精品18| 99精品久久久久人妻精品| 可以在线观看毛片的网站| 少妇人妻一区二区三区视频| 国产亚洲av嫩草精品影院| 在线观看舔阴道视频| 一进一出好大好爽视频| 桃色一区二区三区在线观看| 黄色日韩在线| 久久国产乱子伦精品免费另类| 国产成人精品久久二区二区91| 国产高清三级在线| 亚洲精品在线观看二区| 午夜福利在线观看吧| 人人妻人人看人人澡| 久久婷婷人人爽人人干人人爱| 18禁裸乳无遮挡免费网站照片| 欧美一级a爱片免费观看看| 欧洲精品卡2卡3卡4卡5卡区| 欧美日韩黄片免| 男女之事视频高清在线观看| 国产精品一区二区免费欧美| 99国产极品粉嫩在线观看| 长腿黑丝高跟| 91在线精品国自产拍蜜月 | 在线免费观看不下载黄p国产 | 在线观看66精品国产| 欧美性猛交╳xxx乱大交人| xxx96com| 国产av在哪里看| a级毛片在线看网站| 国产精品野战在线观看| 午夜福利欧美成人| 男人和女人高潮做爰伦理| 亚洲一区二区三区不卡视频| 宅男免费午夜| 亚洲一区高清亚洲精品| 99视频精品全部免费 在线 | 欧美中文综合在线视频| 久久久久久九九精品二区国产| 精品免费久久久久久久清纯| 国产aⅴ精品一区二区三区波| 人人妻人人澡欧美一区二区| 美女cb高潮喷水在线观看 | 一二三四社区在线视频社区8| 精品久久蜜臀av无| 男人舔奶头视频| 这个男人来自地球电影免费观看| 中文字幕av在线有码专区| 久久天堂一区二区三区四区| 久久久久性生活片| 精品国产超薄肉色丝袜足j| 香蕉丝袜av| 国产久久久一区二区三区| 精品国产超薄肉色丝袜足j| 亚洲欧美日韩卡通动漫| 国产高清videossex| 每晚都被弄得嗷嗷叫到高潮| 免费观看人在逋| 国产激情久久老熟女| 97碰自拍视频| 制服丝袜大香蕉在线| svipshipincom国产片| av在线蜜桃| 男女视频在线观看网站免费| 亚洲av成人精品一区久久| 亚洲国产精品sss在线观看| 国产淫片久久久久久久久 | 男女下面进入的视频免费午夜| 亚洲人与动物交配视频| 亚洲国产高清在线一区二区三| 欧美成人性av电影在线观看| 一级毛片高清免费大全| 国产欧美日韩一区二区三| 国产成人欧美在线观看| 18禁观看日本| 青草久久国产| 天天一区二区日本电影三级| 听说在线观看完整版免费高清| 怎么达到女性高潮| 久久亚洲精品不卡| 99热6这里只有精品| 欧美三级亚洲精品| 免费搜索国产男女视频| 久久久久免费精品人妻一区二区| 日韩欧美三级三区| 色av中文字幕| 男人舔奶头视频| 国产亚洲精品久久久com| 亚洲国产精品合色在线| 欧美日韩中文字幕国产精品一区二区三区| 欧美国产日韩亚洲一区| 亚洲美女黄片视频| 在线观看日韩欧美| 国产精品亚洲一级av第二区| 午夜亚洲福利在线播放| 国产1区2区3区精品| 男女床上黄色一级片免费看| 色av中文字幕| 亚洲精品一区av在线观看| 欧美色视频一区免费| 久久香蕉精品热| 成人午夜高清在线视频| 搡老熟女国产l中国老女人| 国产亚洲欧美在线一区二区| 免费观看精品视频网站| 黄片小视频在线播放| 成熟少妇高潮喷水视频| 亚洲美女黄片视频| 中文字幕精品亚洲无线码一区| 免费在线观看影片大全网站| 桃红色精品国产亚洲av| 亚洲人成网站在线播放欧美日韩| 亚洲欧美一区二区三区黑人| 看黄色毛片网站| 亚洲av美国av| 国产 一区 欧美 日韩| 99久久精品热视频| 亚洲一区高清亚洲精品| 此物有八面人人有两片| 别揉我奶头~嗯~啊~动态视频| 我的老师免费观看完整版| 久久久色成人| 在线观看66精品国产| 18禁裸乳无遮挡免费网站照片| 熟女电影av网| 久久中文字幕一级| 99久久精品一区二区三区| www.999成人在线观看| 国产又黄又爽又无遮挡在线| 一进一出好大好爽视频| 日本在线视频免费播放| 色噜噜av男人的天堂激情| 欧美丝袜亚洲另类 | 精品不卡国产一区二区三区| 亚洲aⅴ乱码一区二区在线播放| 国产伦一二天堂av在线观看| 亚洲中文av在线| 国产精品野战在线观看| 亚洲精品美女久久av网站| 99精品在免费线老司机午夜| 久久久久久久久久黄片| www.熟女人妻精品国产| 亚洲国产看品久久| 99久久综合精品五月天人人| 巨乳人妻的诱惑在线观看| 美女 人体艺术 gogo| 欧美+亚洲+日韩+国产| 国产成人av教育| 国内精品美女久久久久久| 嫁个100分男人电影在线观看| 白带黄色成豆腐渣| 国产高清有码在线观看视频| 日韩国内少妇激情av| 一夜夜www| 久久久久国产精品人妻aⅴ院| 黄频高清免费视频| 天天一区二区日本电影三级| 国产精品自产拍在线观看55亚洲| 中文字幕av在线有码专区| 欧美一区二区国产精品久久精品| 美女被艹到高潮喷水动态| 亚洲av日韩精品久久久久久密| 国产午夜精品论理片| 日韩欧美免费精品| 国内精品一区二区在线观看| 欧美zozozo另类| 亚洲国产精品合色在线| 国产成人精品无人区| 成人高潮视频无遮挡免费网站| 岛国在线免费视频观看| 搞女人的毛片| 一夜夜www| 成人高潮视频无遮挡免费网站| 亚洲精品中文字幕一二三四区| 又黄又爽又免费观看的视频| 色播亚洲综合网| 在线观看66精品国产| 男人的好看免费观看在线视频| 午夜两性在线视频| 欧美色视频一区免费| 国产爱豆传媒在线观看| x7x7x7水蜜桃| 国产三级在线视频| 久久精品国产99精品国产亚洲性色| 国产精品久久久av美女十八| 国产成人啪精品午夜网站| 国内揄拍国产精品人妻在线| 亚洲第一电影网av| 亚洲av免费在线观看| 国内精品久久久久精免费| 19禁男女啪啪无遮挡网站| 国产成人精品久久二区二区免费| 国产精品爽爽va在线观看网站| 怎么达到女性高潮| 视频区欧美日本亚洲| 欧美乱码精品一区二区三区|